Tags : Movantik

AstraZeneca to Divest Global Rights of Movantik (naloxegol) to RedHill

Shots: AstraZeneca to receive $52.5M up front and a non-contingent payment of $15M in 2021 while RedHill to get global rights of Movantik (Ex- EU, Canada and Israel). The divestiture allows AstraZeneca to focus on main therapy areas and is expected to be completed in Q1’20 AstraZeneca will transfer it 2015 co-commercialization agreement with Daiichi […]Read More